![Bionyra Pharma Launches with 5M to Advance Inflammation Treatments Led by Veteran Executives]](https://i3.wp.com/medcitynews.com/wp-content/uploads/sites/7/2026/06/Frederic_Marrache_BionyraPharma.jpg?ssl=1 "Bionyra Pharma Launches with 5M to Advance Inflammation Treatments Led by Veteran Executives]")
Bionyra Pharma Launches with $165M to Advance Inflammation Treatments Led by Veteran Executives]
Bionyra Pharma, a new inflammatory disease-focused biotechnology company, has emerged from stealth with $165 million in Series A funding and a pipeline of clinical-stage assets targeting key inflammatory pathways. The company is led by Frédéric Marrache, a veteran of Sanofi where he served as global project head for clinical development in immunology and inflammation, playing a key role in the growth of Dupixent.
The funding round was co-led by Jeito Capital and Sofinnova Partners, with participation from Sanofi Ventures, Arkin Bio, Sixty Degree Capital, Vives Partners, and Apollo Health Ventures. Sofinnova, which co-founded the company with Marrache, leveraged its life sciences investment expertise to identify and license three clinical-stage assets for Bionyra.
The lead program, BYN-002, is a monoclonal antibody targeting TL1A, a protein involved in gastrointestinal inflammation. Designed with half-life extension technology, it is currently in Phase 1 testing and could potentially enable dosing every three to six months. TL1A is also being pursued by Teva-Sanofi (duvakitug), Merck (tulisokibart), Roche (afimkibart), and AbbVie (ABBV-701) in mid-to-late stage trials for ulcerative colitis and Crohn’s disease.
BYN-003, another clinical-stage asset from TrueLab Biopharmaceutical, is a bispecific antibody targeting both TL1A and IL-23p19. The IL-23p19 target is addressed by blockbuster drugs Skyrizi and Tremfya. Early data suggests the monospecific TL1A antibody has favorable immunogenicity profiles, which Marrache believes will translate to the bispecific version.
The third asset, BYN-001, is a monoclonal antibody targeting IL-25, currently in late-preclinical development for atopic dermatitis and type 2 inflammation. Licensed from NovaRock Biotherapeutics, it represents Bionyra’s entry into the atopic dermatitis market.
Bionyra holds global rights to its licensed assets excluding Greater China. The company plans to advance its three lead programs toward proof-of-concept data by the end of 2028, which will inform potential expansion into additional indications including fibrosis, where TL1A also plays a role.